title: N-terminal-pro-B-type natriuretic peptide during pharmacological heart rate reduction in hyperthyroidism.
abstract: We hypothesized that elevated N-terminal-pro-B-type natriuretic peptide levels in hyperthyroidism are mainly driven by increased metabolism due to excess thyroid hormones. Therefore, serum levels of N-terminal-pro-B-type natriuretic peptide were studied during reduced cardiac work load by means of pharmacologically induced heart rate reduction in untreated hyperthyroidism. We designed a noncontrolled interventional study. Eighteen women with newly diagnosed hyperthyroidism were evaluated (including an echocardiography) before and after pharmacological heart rate reduction with 360 mg verapamil daily for 6 days. Before treatment, N-terminal-pro-B-type natriuretic peptide was independently associated with thyroid function (free triiodothyronine-index, r=0.64, p=0.001) and the hemoglobin concentration (r=-0.36, p=0.031). The verapamil treatment induced a decrease in parameters reflecting cardiac function; resting heart rate [from mean 97 to 80 beats per min (17.5%), p<0.001] and mean arterial pressure (8.5%, p=0.001). Median N-terminal-pro-B-type natriuretic peptide increased insignificantly from 224 to 240 pg/ml (p=0.31). Thyrotrotrophin levels were totally suppressed (<0.001 mU/l), free thyroxine-index decreased from median 319 to 315 arbitrary units (p=0.039) and free triiodothyronine-index increased from 8.6 to 9.9 arbitrary units (p=0.010). No changes in echocardiographic parameters were observed. A decrease in resting heart rate in untreated hyperthyroidism due to verapamil treatment did not result in decreasing N-terminal-pro-B-type natriuretic peptide levels. Thus elevated N-terminal-pro-B-type natriuretic peptide in hyperthyroidism seems mainly a result of high metabolism due to excess thyroid hormones rather than increased cardiac work load.
authors.affiliation: Department of Cardiology and Endocrinology E, Frederiksberg University Hospital, Frederiksberg, Denmark. haurum@dadlnet.dk
authors.forename: M
authors.initials: M
authors.lastname: Schultz
authors.forename: C
authors.initials: C
authors.lastname: Kistorp
authors.forename: P
authors.initials: P
authors.lastname: Corell
authors.forename: H U
authors.initials: HU
authors.lastname: Andersen
authors.forename: A
authors.initials: A
authors.lastname: Jarlov
authors.forename: J
authors.initials: J
authors.lastname: Faber
mesh_terms: D000328:Adult; D003718:Denmark; D005260:Female; D006339:Heart Rate / Q000187:drug effects*; D006801:Humans; D006980:Hyperthyroidism / Q000097:blood / Q000188:drug therapy*; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood*; D013960:Thyroid Function Tests; D014700:Verapamil / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D020097:Natriuretic Peptide, Brain; D014700:Verapamil